News

Filter

US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma

15-05-2013

US and European hematological oncologists surveyed by health care advisory firm Decision Resources indicate…

carfilzomibEuropeKyprolisMarkets & MarketingNorth AmericaOncologyOno PharmaceuticalOnyx PharmaceuticalsPharmaceuticalpomalidomide

VentiRx collaborates with Celgene on cancer drug candidate; pomalidomide update

05-10-2012

VentiRx Pharmaceuticals, a privately held US biopharmaceutical company dedicated to the development of…

BiotechnologyCelgeneLicensingNorth AmericaOncologyPharmaceuticalpomalidomideRegulationVentiRx PharmaceuticalsVTX-2337

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine

21-09-2012

US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

Celgene slumps as it pulls new EU indication filing for Revlimid

22-06-2012

Celgene International, the European subsidiary of USA-based Celgene Corp (Nasdaq: CELG), has provided…

BiotechnologyCelgeneEuropeFinancialOncologyPharmaceuticalpomalidomideRegulationRevlimid

Back to top